Conjugated Pneumococcal Vaccine
Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
H. Lee Moffitt Cancer Center and Research InstitutevaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
86 Active assets in the Primary Mediastinal Large B-Cell Lymphoma (PMBCL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ifosfamide David Bond, MD | Phase 4 | BBB |
Inno-206 Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 4 | BBB |
ETOPOSIDE University of Washington | Phase 4 | BBB |
ETOPOSIDE University of Washington | Phase 4 | BBB |
Inno-206 University of Washington | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Conjugated Pneumococcal Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →